Trial Profile
A multicenter randomized 52 week treatment double-blind, triple-dummy parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Indacaterol/mometasone (Primary) ; Mometasone; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms PALLADIUM
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals
- 25 Jul 2022 Results of post-hoc analysis assessing efficacy and safety of IND/MF versus SAL/FLU in Asian patients with inadequately controlled asthma from two (PALLADIUM and IRIDIUM) published in the Journal of Asthma
- 24 Jan 2022 A review outlining the unique strategy used in the accelerated development of IND/GLY/MF that combined various approaches comprising data from 3 study (QUARTZ and PALLADIUM evaluated IND/MF while IRIDIUM and ARGON evaluated IND/GLY/MF) published in the Advances in Therapy
- 22 May 2021 Results (n=698) of pooled analysis from 2 trials (PALLADIUM and IRIDIUM) assessing the population pharmacokinetic (popPK) analysis of Indacaterol/Glycopyrronium/Mometasone Furoate and estimate the effect of covariates on their pharmacokinetics in patients with asthma, published in the European Journal of Drug Metabolism and Pharmacokinetics.